# Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy

> **NCT05388058** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 40 (actual)

## Conditions studied

- Chemotherapy-Induced Peripheral Neuropathy
- Malignant Solid Neoplasm

## Interventions

- **DRUG:** Cannabidiol
- **DRUG:** Placebo Administration
- **OTHER:** Quality-of-Life Assessment
- **OTHER:** Questionnaire Administration

## Key facts

- **NCT ID:** NCT05388058
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-09
- **Primary completion:** 2023-07-14
- **Final completion:** 2023-07-28
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2026-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05388058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05388058, "Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT05388058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*